LncRNA DLGAP1-AS2 Regulates MiR-503/cyclin D1 to Promote Cell Proliferation in Non-small Cell Lung Cancer

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2021 Aug 29

PMID 34454450

Citations 7

Authors

Lu Wang

Lei Tang

Tengfei Ge

Feng Zhu

Dan Liu

Hua Guo

Peng Qian

Ning Xu

Affiliations

Soon will be listed here.

Abstract

Background: LncRNA DLGAP1-AS2 plays an oncogenic role in glioma, while its role in other cancers is unknown. This study aimed to study the role of DLGAP1-AS2 in non-small cell lung cancer (NSCLC).

Methods: Expression of DLGAP1-AS2 in NSCLC and paired non-tumor tissues from 64 NSCLC patients and the prognostic value of DLGAP1-AS2 for NSCLC were analyzed by performing a 5-year follow-up study. The interaction between DLGAP1-AS2 and miR-503 was confirmed by dual luciferase reporter assay, and their relationship was explored in NSCLC cells transfected with DLGAP1-AS2 expression vector or miR-503 mimic. The roles of DLGAP1-AS2 and miR-503 in regulating cyclin D1 expression were analyzed by RT-qPCR and Western blot. Cell proliferation was analyzed by CCK-8 assay.

Results: DLGAP1-AS2 was upregulated in NSCLC and predicted poor survival. Interaction between DLGAP1-AS2 and miR-503 was confirmed by dual luciferase activity assay. Overexpression experiments showed that DLGAP1-AS2 and miR-503 overexpression failed to significantly affect the expression of each other. Interestingly, DLGAP1-AS2 overexpression upregulated cyclin D1, a target of miR-503, increased cell proliferation and reduced the effects of miR-503 overexpression on cyclin D1 expression and cell proliferation.

Conclusions: DLGAP1-AS2 may regulate miR-503/cyclin D1 to promote cell proliferation in NSCLC.

Citing Articles

Improvement of carboplatin chemosensitivity in lung cancer cells by siRNA-mediated downregulation of DLGAP1-AS2 expression.

Alamdari S, Mohammadzadeh R, Amini M, Najafi S, Baradaran B, Bahojb Mahdavi S Sci Rep. 2025; 15(1):7971.

PMID: 40055367 PMC: 11889186. DOI: 10.1038/s41598-025-87649-6.

Various LncRNA Mechanisms in Gene Regulation Involving miRNAs or RNA-Binding Proteins in Non-Small-Cell Lung Cancer: Main Signaling Pathways and Networks.

Braga E, Fridman M, Burdennyy A, Loginov V, Dmitriev A, Pronina I Int J Mol Sci. 2023; 24(17).

PMID: 37686426 PMC: 10487663. DOI: 10.3390/ijms241713617.

MiR-503 pleiotropically regulates epithelial-mesenchymal transition and targets PTK7 to control lung cancer metastasis.

Tsai T, Gow C, Liu Y, Tsai M, Chang T, Wu S Cancer Med. 2023; 12(13):14511-14525.

PMID: 37212485 PMC: 10358207. DOI: 10.1002/cam4.6116.

Long noncoding RNA DLGAP1-AS2 promotes tumorigenesis and metastasis by regulating the Trim21/ELOA/LHPP axis in colorectal cancer.

Wang X, Cheng H, Zhao J, Li J, Chen Y, Cui K Mol Cancer. 2022; 21(1):210.

PMID: 36376892 PMC: 9664729. DOI: 10.1186/s12943-022-01675-w.

DLGAP1-AS2 promotes human colorectal cancer progression through trans-activation of Myc.

Ren C, Han H, Pan J, Chang Q, Wang W, Guo X Mamm Genome. 2022; 33(4):672-683.

PMID: 36222892 DOI: 10.1007/s00335-022-09963-y.

References

Rahal Z, El Nemr S, Sinjab A, Chami H, Tfayli A, Kadara H . Smoking and Lung Cancer: A Geo-Regional Perspective. Front Oncol. 2017; 7:194. PMC: 5585135. DOI: 10.3389/fonc.2017.00194. View

Adjei A . Lung Cancer Worldwide. J Thorac Oncol. 2019; 14(6):956. DOI: 10.1016/j.jtho.2019.04.001. View

Richards T, Henley S, Puckett M, Weir H, Huang B, Tucker T . Lung cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study. Cancer. 2017; 123 Suppl 24:5079-5099. PMC: 5812722. DOI: 10.1002/cncr.31029. View

Yang H, Liu P, Zhang J, Peng X, Lu Z, Yu S . Long noncoding RNA MIR31HG exhibits oncogenic property in pancreatic ductal adenocarcinoma and is negatively regulated by miR-193b. Oncogene. 2015; 35(28):3647-57. PMC: 4947634. DOI: 10.1038/onc.2015.430. View

Matyi S, Jackson J, Garrett K, Deepa S, Unnikrishnan A . The effect of different levels of dietary restriction on glucose homeostasis and metabolic memory. Geroscience. 2018; 40(2):139-149. PMC: 5964050. DOI: 10.1007/s11357-018-0011-5. View

Jiang L, Zhao Z, Zheng L, Xue L, Zhan Q, Song Y . Downregulation of miR-503 Promotes ESCC Cell Proliferation, Migration, and Invasion by Targeting Cyclin D1. Genomics Proteomics Bioinformatics. 2017; 15(3):208-217. PMC: 5487524. DOI: 10.1016/j.gpb.2017.04.003. View

Long J, Ou C, Xia H, Zhu Y, Liu D . MiR-503 inhibited cell proliferation of human breast cancer cells by suppressing CCND1 expression. Tumour Biol. 2015; 36(11):8697-702. DOI: 10.1007/s13277-015-3623-8. View

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018; 379(24):2342-2350. DOI: 10.1056/NEJMoa1809697. View

Schrank Z, Chhabra G, Lin L, Iderzorig T, Osude C, Khan N . Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance. Cancers (Basel). 2018; 10(7). PMC: 6071023. DOI: 10.3390/cancers10070224. View

10.

Mender I, LaRanger R, Luitel K, Peyton M, Girard L, Lai T . Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. Neoplasia. 2018; 20(8):826-837. PMC: 6037876. DOI: 10.1016/j.neo.2018.06.002. View

11.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

12.

Oberndorfer F, Mullauer L . Molecular pathology of lung cancer: current status and perspectives. Curr Opin Oncol. 2017; 30(2):69-76. DOI: 10.1097/CCO.0000000000000429. View

13.

Sperduto P, Yang T, Beal K, Pan H, Brown P, Bangdiwala A . Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2016; 3(6):827-831. PMC: 5824323. DOI: 10.1001/jamaoncol.2016.3834. View

14.

Navarro-Martin A, Aso S, Cacicedo J, Arnaiz M, Navarro V, Rosales S . Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months. J Thorac Oncol. 2016; 11(7):1101-11. DOI: 10.1016/j.jtho.2016.03.021. View

15.

Braun D, Bachstetter A, Sudduth T, Wilcock D, Watterson D, Van Eldik L . Genetic knockout of myosin light chain kinase (MLCK210) prevents cerebral microhemorrhages and attenuates neuroinflammation in a mouse model of vascular cognitive impairment and dementia. Geroscience. 2019; 41(5):671-679. PMC: 6885026. DOI: 10.1007/s11357-019-00072-4. View

16.

Dias M, Linhas R, Campainha S, Conde S, Barroso A . Lung cancer in never-smokers - what are the differences?. Acta Oncol. 2017; 56(7):931-935. DOI: 10.1080/0284186X.2017.1287944. View

17.

Noguchi T, Toiyama Y, Kitajima T, Imaoka H, Hiro J, Saigusa S . miRNA-503 Promotes Tumor Progression and Is Associated with Early Recurrence and Poor Prognosis in Human Colorectal Cancer. Oncology. 2016; 90(4):221-31. DOI: 10.1159/000444493. View

18.

Farazi T, Spitzer J, Morozov P, Tuschl T . miRNAs in human cancer. J Pathol. 2010; 223(2):102-15. PMC: 3069496. DOI: 10.1002/path.2806. View

19.

Barta J, Powell C, Wisnivesky J . Global Epidemiology of Lung Cancer. Ann Glob Health. 2019; 85(1). PMC: 6724220. DOI: 10.5334/aogh.2419. View

20.

Miao W, Li N, Gu B, Yi G, Su Z, Cheng H . LncRNA DLGAP1-AS2 modulates glioma development by up-regulating YAP1 expression. J Biochem. 2020; 167(4):411-418. DOI: 10.1093/jb/mvz108. View